An Open Label Extension Study Evaluating the Safety and Efficacy of Long Term Dosing of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura

Trial Profile

An Open Label Extension Study Evaluating the Safety and Efficacy of Long Term Dosing of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura

Completed
Phase of Trial: Phase II/III

Latest Information Update: 07 Feb 2017

At a glance

  • Drugs Romiplostim (Primary)
  • Indications Idiopathic thrombocytopenic purpura; Immune thrombocytopenic purpura
  • Focus Adverse reactions
  • Sponsors Kyowa Hakko Kirin
  • Most Recent Events

    • 18 Nov 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top